Navigation Links
Isis Pharmaceuticals to Present a General Corporate Update at Its 2010 Annual Meeting of Stockholders and Open House

CARLSBAD, Calif., May 26 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2010 Annual Meeting of Stockholders and Open House on June 2 from 2:00 p.m. to 6:00 p.m. Pacific Time in Carlsbad, CA.  

The agenda for the meeting is as follows:

2:00 p.m.2:15 p.m. Annual Meeting of Stockholders (stockholders of record as of April 6, 2010 only)

2:15 p.m.2:45 p.m. Corporate Presentation – Stanley T. Crooke, Chairman and CEO, Isis

2:45 p.m.3:00 p.m. Mipomersen Commercialization Presentation – John Butler, Genzyme

The agenda for the scientific session is as follows:

3:00 p.m.4:00 p.m. Mipomersen Lipid-Expert Panel Discussion

4:00 p.m.6:00 p.m. Poster Presentation

The mipomersen panel will be comprised of three renowned physicians: Dr. William Cromwell, Dr. Willis Maddrey and Dr. Joseph Witztum and moderated by Dr. Bruce Turner, healthcare fund manager at Bank of America.  Questions for the panelists may be submitted through Isis' Company Web site,, in advance of the meeting.

A live audio webcast of the presentations will be available on the "Investors & Media" section of the Company's Web site,  A replay of the presentations will be available on the Isis Web site within 48 hours and will be archived for a limited time.


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alzheimers Drug Discovery Foundation Funds American Life Science Pharmaceuticals, Inc to Move Novel Therapeutic Towards Clinic
2. China Yongxin Pharmaceuticals Reports First Quarter 2010 Financial Results
3. Epix Pharmaceuticals, Inc. Announces a Change in the May 28, 2010 Auction Sale of Epix Imaging Agents to June 22, 2010
4. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
5. Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference
6. Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
9. WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals
10. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
11. Isis Pharmaceuticals to Discuss Its Cancer Franchise in a Conference Call on Wednesday, May 19
Post Your Comments:
(Date:11/30/2015)... IRVINE, Calif. and REHOVOT, Israel ... privately held specialty pharmaceutical company focused on acquiring and ... disorders, today announced the appointment of Keith A. ... directors. Gregory J. Flesher , chief executive ... experience in building successful organizations.  As chairman, he will ...
(Date:11/30/2015)... , November 30, 2015 ... Breast Care has entered into a multi-year agreement ... practice. This will allow Kentucky Breast Care to increase ... exceptional care for their patients. --> ... Breast Care has entered into a multi-year agreement ...
(Date:11/29/2015)... --  Royal Philips  (NYSE: PHG, AEX: PHIA) revealed a ... Radiological Society of North America Annual Meeting (RSNA), beginning ... Chicago . Visitors to the Philips ... of integrated Diagnostic Imaging, Clinical Informatics, Image Guided Therapy ... workflow and create a superior patient experience. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Scott ... one of a select few plastic surgeons in the New York City area ... SculpSure™ is the world’s first heat-induced laser treatment for fat loss in the ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today that ... Program with competencies in the Application Development, demonstrating a “best-in-class” ability and ...
(Date:11/30/2015)... MN (PRWEB) , ... November 30, 2015 , ... ... of a new product dealer. Joining more than 30 HealthPostures’ dealers located throughout ... foot space and increase the number of corporate, industrial, manufacturing and government workers ...
(Date:11/30/2015)... ... November 30, 2015 , ... CTI ... services which empower organizations through communication analytics, announced today that their Proteus® VoIP ... manage their service quality. , Proteus® VoIP QMS (Quality Management System) ...
(Date:11/29/2015)... St. Petersburg, FL (PRWEB) , ... November 30, 2015 , ... The Cyber Monday deal ... webstore. , It is the right time to get gifts for the skin care lover ... bow on top filled with serums . This year, the 3 serums are staples: Collagen, ...
Breaking Medicine News(10 mins):